D. E. Shaw & Co. Inc. Trims Holdings in AtriCure, Inc. (NASDAQ:ATRC)

D. E. Shaw & Co. Inc. reduced its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 42.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,462 shares of the medical device company's stock after selling 49,834 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.14% of AtriCure worth $2,062,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. purchased a new stake in AtriCure in the 4th quarter valued at about $9,168,000. Kennedy Capital Management LLC raised its stake in shares of AtriCure by 29.8% during the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after acquiring an additional 172,648 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of AtriCure by 37.1% in the fourth quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after purchasing an additional 167,476 shares during the period. Oberweis Asset Management Inc. bought a new position in AtriCure in the fourth quarter worth approximately $4,630,000. Finally, Dimensional Fund Advisors LP increased its holdings in AtriCure by 24.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock worth $21,398,000 after purchasing an additional 136,015 shares during the period. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ATRC shares. Needham & Company LLC dropped their price target on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. JPMorgan Chase & Co. dropped their target price on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, March 27th. Stifel Nicolaus raised their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Oppenheimer upped their price target on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Finally, Piper Sandler lifted their price objective on shares of AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AtriCure currently has a consensus rating of "Buy" and an average target price of $50.67.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now owns 17,828 shares in the company, valued at $679,603.36. This represents a 25.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.50% of the stock is currently owned by company insiders.

AtriCure Stock Down 0.3%

Shares of NASDAQ ATRC traded down $0.10 during trading hours on Monday, hitting $32.71. 330,069 shares of the stock were exchanged, compared to its average volume of 650,988. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11. The firm has a fifty day moving average price of $32.34 and a 200-day moving average price of $34.75. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.62 billion, a PE ratio of -34.43 and a beta of 1.57.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The firm had revenue of $123.62 million during the quarter, compared to analyst estimates of $122.92 million. During the same quarter in the prior year, the business posted ($0.28) EPS. The business's revenue for the quarter was up 13.5% compared to the same quarter last year. On average, sell-side analysts expect that AtriCure, Inc. will post -0.6 EPS for the current year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.